Actively Recruiting
Safety Evaluation of Two Doses of Chlamydia Trachomatis mRNA Vaccine Candidate in Adults with and without Prior Exposure
Led by Sanofi · Updated on 2026-11-02
80
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety of two different doses of a Chlamydia mRNA vaccine candidate in adults. The study includes participants aged 18 to 29 years who do not have prior exposure to Chlamydia trachomatis, and those aged 18 to 44 years who are seropositive. The study aims to assess safety and possibly detect early immune responses to the vaccine. Participants are divided into two groups receiving either the first or second dose of the vaccine, or a placebo, given as three intramuscular injections. There are separate cohorts based on Chlamydia trachomatis serostatus. The study lasts about 18 months for each participant, including a 12-month follow-up after the last injection. During the study, participants will be monitored for immediate reactions after injections, injection site and systemic symptoms in the days following, and any adverse events for up to a year after vaccination. Laboratory tests will also be performed to check for abnormal results. Researchers will assess all serious adverse events throughout the study to evaluate safety comprehensively.
CONDITIONS
Brief Title
Phase 1 Study of Chlamydia Trachomatis mRNA Vaccine in Adults.
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here